A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, ...

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

The emergence of vorasidenib, the first targeted therapy for certain gliomas with IDH mutations, has ignited a wave of excitement in both patient and physician spaces. But following the approval, some ...

Treatment with vorasidenib significantly improved progression free survival compared with placebo. The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib) for the treatment of adult ...

The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global ...

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 ...

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...